[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359737-105":59,"doc-detail-359737-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteomic-profiling-and-molecular-reclassification-of-high-grade-serous-ovarian-cancer-identifies-prognostic-subtypes-and-immunotherapy-biomarkers","Proteomic profiling and molecular reclassification of high-grade serous ovarian cancer identifies prognostic subtypes and immunotherapy biomarkers","","High-grade serous ovarian cancer (HGSOC) shows marked molecular heterogeneity and limited effective treatments, creating a need for proteomics-driven biomarker discovery across disease stages. Proteomic profiling of 116 primary HGSOC tumours, supported by integrative bioinformatics with clinical annotation and experimental validation, delineates proteomic inflection during progression. FIGO stage IIA emerges as a key transition, linked to GOSR2-SEC24D control of immune infiltration. Unsupervised clustering defines three proteomic subtypes and immune-contexture subtypes with prognostic relevance, including an ISG15/ITGB2/RELA subgroup suggestive of immunotherapy susceptibility.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteomic-profiling-and-molecular-reclassification-of-high-grade-serous-ovarian-cancer-identifies-prognostic-subtypes-and-immunotherapy-biomarkers/359737/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteomic-profiling-and-molecular-reclassification-of-high-grade-serous-ovarian-cancer-identifies-prognostic-subtypes-and-immunotherapy-biomarkers/359737.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What disease stage is identified as a key molecular transition in HGSOC?","Question",{"text":112,"@type":113},"FIGO stage IIA is identified as a crucial inflection point distinguishing early- from advanced-stage disease, marked by a shift in proteomic programmes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the GOSR2-SEC24D axis relate to tumour immune infiltration?",{"text":117,"@type":113},"GOSR2 interacts with SEC24D to inhibit CXCL9 and CXCL12 secretion, leading to reduced CD8+ T cell infiltration during the early-to-advanced transition.",{"name":119,"@type":110,"acceptedAnswer":120},"What proteomic and immune-contexture subtypes were defined, and why do they matter?",{"text":121,"@type":113},"Unsupervised clustering defines three reproducible proteomic subtypes (S-I to S-III) and three immune-contexture subtypes (IC1 to IC3), each associated with distinct clinical outcomes and tumour immune microenvironment states.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359737,1790205958,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Articles  \nProteomic profiling and molecular reclassification of high-grade serous ovarian cancer identifies prognostic subtypes and immunotherapy biomarkers  \nMengyan Tu,a,b,e Sangsang Tang,a,b,e Qiao Zhang,c,e Tianchen Guo,a,b,e Yixuan Cen,a,b Xiaomeng Xu,c Shenglong Wu,a,b Xin Chen,a,b Weiguo Lu,a,b,d,∗ Chen Ding,c,∗∗ and Junfen Xua,b,d,∗∗∗  \naDepartment of Gynaecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang, China  \nbZhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynaecological Diseases, Hangzhou, 310006, Zhejiang, China cState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, 200433, China  \ndZhejiang Provincial Clinical Research Centre for Obstetrics and Gynaecology, Hangzhou, 310058, Zhejiang, China  \nSummary  \nBackground High-grade serous ovarian cancer (HGSOC) is the most lethal histological subtype of ovarian cancer, exhibiting significant heterogeneity and limited therapeutic options. A comprehensive characterisation of proteomic landscape across disease stages is needed to identify actionable biomarkers and therapeutic targets.  \nMethods We performed proteomic profiling of 116 primary HGSOC tumours, followed by integrative bioinformatics analyses incorporating clinical annotation. Key findings were validated using multiplex immunohistochemistry, in vitro and in vivo functional assays, and external datasets.  \nFindings We identified FIGO stage IIA as a crucial turning point distinguishing early-from advanced-stage disease, marked by a transition from oxidative stress to cell cycle-driven programmes. Trajectory analysis of tumour progression revealed GOSR2 as a key regulator of stage transition. Mechanistically, GOSR2 interacted with SEC24D to inhibit the secretion of CXCL9 and CXCL12, resulting in reduced CD8+ T cell infiltration. Unsupervised clustering defined three reproducible proteomic subtypes (S-I to S-III), which were validated in TCGA and single-cell transcriptomic datasets and associated with distinct clinical outcomes. The S-III subtype was characterised by ECM-receptor interaction, immune evasion, and poor prognosis. Transcription factors network analysis identified regulators potentially driving these phenotypes. In parallel, three immune-contexture subtypes (IC1-IC3) were delineated, reflecting differential tumour immune microenvironment states with prognostic relevance. Advanced-stage HGSOC was further stratified using ISG15, ITGB2, and RELA expression, idenfifying a subgroup with potential susceptibility to immunotherapy.  \nInterpretation Our findings provide a framework for biomarker-guided stratification and the development of precision therapeutic strategies in HGSOC.  \nFunding Key R&D Program of Zhejiang, NSFC, and 4+X CRP ofWHZJU.  \nCopyright © 2026 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nKeywords: High-grade serous ovarian cancer; Proteomics; Molecular subtyping; Precision therapy  \n*Corresponding author. Department of Gynaecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, \\#1 Xueshi Road, Hangzhou, 310006, China.  \n**Corresponding author. State Key Laboratory of Genetic Engineering and Collaborative Innovation Centre for Genetics and Development, School of Life Sciences, Institute of Biomedical Sciences, Human Phenome Institute, Zhongshan Hospital, Fudan University, Shanghai 200433, China.  \n***Corresponding author. Department of Gynaecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, \\#1 Xueshi Road, Hangzhou, 310006, China.  \nE-mail addresses: [lbwg@zju.edu.cn](lbwg@zju.edu.cn) (W. Lu), [chend@fudan.edu.cn](chend@fudan.edu.cn) (C. Ding), [xjfzu@zju.edu.cn](xjfzu@zju.edu.cn) (J. Xu).  \neThese authors contr","cbCain24uBFXzWGB","https://ap.wps.com/l/cbCain24uBFXzWGB","pdf",17590350,27,"English","# Background\n# Methods\n# Findings\n# Interpretation\n# Research in context\n## Evidence before this study\n## Added value of this study","[{\"question\":\"What disease stage is identified as a key molecular transition in HGSOC?\",\"answer\":\"FIGO stage IIA is identified as a crucial inflection point distinguishing early- from advanced-stage disease, marked by a shift in proteomic programmes.\"},{\"question\":\"How does the GOSR2-SEC24D axis relate to tumour immune infiltration?\",\"answer\":\"GOSR2 interacts with SEC24D to inhibit CXCL9 and CXCL12 secretion, leading to reduced CD8+ T cell infiltration during the early-to-advanced transition.\"},{\"question\":\"What proteomic and immune-contexture subtypes were defined, and why do they matter?\",\"answer\":\"Unsupervised clustering defines three reproducible proteomic subtypes (S-I to S-III) and three immune-contexture subtypes (IC1 to IC3), each associated with distinct clinical outcomes and tumour immune microenvironment states.\"}]","Proteomic profiling and molecular reclassification of high-grade serous ovarian cancer identifies prognostic subtypes and immunotherapy biomarkers | PDF",1790137677,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d8aaa79d1736d085952c4a93378945b.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b28ac2a00250c53484793788416e86e4.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/504a7ac531033d57a58baa208e076a5b.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b69e5f225b72b578a495a3b6d76d9ea.webp",980,1306]